2539 |
Remnant Risk of Secondary MACE/ Mortality After Index AMI in Asian Patients |
Kiyuk Chang |
Apr. 20. 15 |
2538 |
Does True Vessel Healing Matter? |
Roxana Mehran |
Apr. 20. 15 |
2537 |
Remnant Risk of Secondary MACE/ Mortality After Index AMI |
Freek W.A. Verheugt |
Apr. 20. 15 |
2536 |
Does Lesion Preparation Matter? |
Kentaro Jujo |
Apr. 20. 15 |
2535 |
Optimal Duration of Dual Antiplatelet Therapy After Implantation of DES: Shorter or Longer? |
Jang-Whan Bae |
Apr. 20. 15 |
2534 |
How Do I Manage My Most Complex CTO? |
Satoru Sumitsuji |
Apr. 20. 15 |
2533 |
Antiplatelet Therapy in ACS: Are New Pharmacological Agents Changing Paradigms Beyond Clopidogrel? |
Soon Jun Hong |
Apr. 20. 15 |
2532 |
Safety Assured: Global Resolute Data |
Rosli Mohd Ali |
Apr. 20. 15 |
2531 |
My Practice with Zilver PTX |
Bryan Ping-Yen Yan |
Apr. 20. 15 |
2530 |
Complex Cases: Complex Lesion with Resolute Onyx |
Seung-Woon Rha |
Apr. 20. 15 |